<DOC>
	<DOCNO>NCT00395772</DOCNO>
	<brief_summary>The purpose study determine optimal dose BAY 59-7939 compare safety effectiveness new drug standard way treatment deep vein thrombosis ( heparin infusion plus one vitamin K antagonist ) , take account new event thrombosis pulmonary embolism bleed risk .</brief_summary>
	<brief_title>Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 Patients With Acute Symptomatic Deep-vein Thrombosis</brief_title>
	<detailed_description>Within U.S. , Johnson &amp; Johnson sponsor .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Confirmed acute symptomatic DVT , i.e . proximal extensive calfvein thrombosis involve least upper third part calf vein , without concomitant symptomatic PE Written inform consent Legal low age limitation ( country specific ) Thrombectomy , insertion caval filter , use fibrinolytic agent treat current episode DVT Other indication VKA PE/DVT More 36 hour prerandomization treatment therapeutic dosage ( LMW ) heparin single dose VKA prior randomization Participation another pharmacotherapeutic study within prior 30 day Creatinine clearance &lt; 30 mL/min , impair liver function ( transaminases &gt; 2 x ULN ) , bacterial endocarditis Life expectancy &lt; 3 month Active bleeding high risk bleed contraindicate treatment ( LMW ) heparin Uncontrolled hypertension : systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 110 mmHg Pregnancy childbearing potential without proper contraceptive measure Any contraindication list label warfarin , acenocoumarol , phenprocoumon , fluindione , UFH , enoxaparin , tinzaparin Systemic treatment azole compound strong CYP3A4 inhibitor ( e.g . ketoconazole , fluconazol , itraconazole , HIV protease inhibitor ) within 4 day prior randomization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Treatment venous thromboembolism</keyword>
</DOC>